Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study

2015 ◽  
Vol 103 (2) ◽  
pp. 243-250 ◽  
Author(s):  
Kazuo Muroi ◽  
Koichi Miyamura ◽  
Masaya Okada ◽  
Takuya Yamashita ◽  
Makoto Murata ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Grade Iii ◽  
Steroid Refractory ◽  
Acute Graft

Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study

2013 ◽  
Vol 98 (2) ◽  
pp. 206-213 ◽  
Author(s):  
Kazuo Muroi ◽  
Koichi Miyamura ◽  
Kazuteru Ohashi ◽  
Makoto Murata ◽  
Tetsuya Eto ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Phase I ◽  
Graft Versus Host Disease ◽  
Allogeneic Bone ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory ◽  
Acute Graft

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

The Lancet ◽  
2008 ◽  
Vol 371 (9624) ◽  
pp. 1579-1586 ◽  
Author(s):  
Katarina Le Blanc ◽  
Francesco Frassoni ◽  
Lynne Ball ◽  
Franco Locatelli ◽  
Helene Roelofs ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Phase Ii Study ◽  
Steroid Resistant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

The Lancet ◽  
2004 ◽  
Vol 363 (9419) ◽  
pp. 1439-1441 ◽  
Author(s):  
Katarina Le Blanc ◽  
Ida Rasmusson ◽  
Berit Sundberg ◽  
Cecilia Götherström ◽  
Moustapha Hassan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease

2013 ◽  
Vol 27 (6) ◽  
pp. 930-937 ◽  
Author(s):  
Naheed Alam ◽  
Eshetu G. Atenafu ◽  
Garwin Tse ◽  
Auro Viswabandya ◽  
Vikas Gupta ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Salvage Therapy ◽  
Host Disease ◽  
Graft Versus Host ◽  
Grade Iii ◽  
Steroid Refractory ◽  
Acute Graft

scholarly journals Mesenchymal stem cells for treatment of severe acute graft-versus-host disease

2006 ◽  
Vol 12 (2) ◽  
pp. 2 ◽  
Author(s):  
O. Ringden ◽  
M. Uzunel ◽  
I. Rasmusson ◽  
M. Remberger ◽  
B. Sundberg ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5304-5304 ◽  
Author(s):  
Katarina Le Blanc ◽  
Francesco Frassoni ◽  
Lynne Ball ◽  
Edoardo Lanino ◽  
Berit Sundberg ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Graft Versus Host Disease ◽  
Acute Gvhd ◽  
Chronic Gvhd ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Abstract Mesenchymal stem cells (MSC) from adult bone marrow have the capacity to differentiate into several mesenchymal tissues and inhibit T-cell alloreactivity in vitro. Within the EBMT MSC expansion consortium we have used MSC to treat grades III–IV acute graft-versus-host disease (GvHD) in 40 patients. The MSC dose was median 1.0 (range 0.4–9) 10^6 cells/kg body weight of the recipient. No side-effects were seen after MSC infusions. Nineteen patients received one dose, 19 patients received two doses, two patients received three and five doses respectively. MSC donors were in five cases HLA-identical sibling donors, 19 haploidentical donors and 41 third-party HLA-mismatched donors. Among the 40 patients treated for severe acute GvHD, 19 had complete responses, nine showed improvement, seven patients did not respond, four had stable disease and one patient was not evaluated due to short follow-up. Twenty-one patients are alive between six weeks up to 3.5 years after transplantation. Nine of these patients have extensive chronic GvHD. One patient with ALL has recurrent leukaemia and one patient has denovo AML of recipient origin. We conclude that MSC have immunomodulatory and tissue repairing effects and should be further explored as treatment of severe acute GvHD in prospective randomized trials.

Sign in / Sign up

Export Citation Format

Share Document